See the DrugPatentWatch profile for cosentyx

Yes, alternative medications to Cosentyx (secukinumab) are available for psoriasis patients with allergies. Secukinumab is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a cytokine involved in the pathogenesis of psoriasis. However, some patients may experience allergic reactions to secukinumab or its excipients. In such cases, alternative medications can be considered.

One alternative medication is ustekinumab (Stelara), which is a human monoclonal antibody that targets the p40 subunit of IL-12 and IL-23, thereby inhibiting the differentiation and activation of T-helper 1 and T-helper 17 cells. Ustekinumab has a different mechanism of action than secukinumab and may be a suitable alternative for patients with allergies to secukinumab.

Another alternative medication is guselkumab (Tremfya), which is a human monoclonal antibody that selectively binds to the p19 subunit of IL-23, thereby inhibiting the differentiation and activation of T-helper 17 cells. Guselkumab also has a different mechanism of action than secukinumab and may be a suitable alternative for patients with allergies to secukinumab.

Other alternative medications for psoriasis include brodalumab (Siliq), ixekizumab (Taltz), and tildrakizumab (Ilumya), which are human monoclonal antibodies that target IL-17 or IL-23. However, the safety and efficacy of these medications should be evaluated on a case-by-case basis, taking into account the patient's medical history, comorbidities, and preferences.

In summary, alternative medications to Cosentyx are available for psoriasis patients with allergies. These alternatives include ustekinumab, guselkumab, brodalumab, ixekizumab, and tildrakizumab, which have different mechanisms of action and may be suitable for patients with allergies to secukinumab.

Sources:

* <https://www.drugs.com/cosentyx.html>
* <https://www.ncbi.nlm.nih.gov/books/NBK537231/>
* <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761071s000lbl.pdf>
* <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761046s000lbl.pdf>
* <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761157s000lbl.pdf>
* <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761133s000lbl.pdf>
* <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761132s000lbl.pdf>
* <https://www.drugpatentwatch.com/drugs/cosentyx>